Merck's remigromig meets primary endpoint in DME phase 2b/3 trial
Merck (NYSE: MRK) announced topline results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000), an investigational tri-specific antibody ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)